Industry Capture

Regulatory capture is the quiet, systemic process by which the industries a government is supposed to oversee instead come to control the agencies, the legislation, and the lawmakers themselves. It is not a conspiracy. It does not require backroom deals or suitcases of cash. It operates through legal lobbying, legitimate campaign contributions, and a revolving door that moves talent between government offices and corporate boardrooms with metronomic regularity. In four industries — pharmaceuticals, defense, fossil fuels, and technology — the capture is so complete that the line between public servant and private interest has effectively dissolved.

This chapter examines each of these industries in turn: the money they spend, the mechanisms they use, and the public costs they impose. The data is drawn from Senate lobbying disclosures, FEC filings, USASpending.gov, state campaign finance databases, and congressional records. Every figure cited is sourced. The pattern is always the same — invest in politics, write the rules, hire the regulators, block reform, and profit.

The four industries profiled here spend a combined $700 million or more each year on federal lobbying alone. That figure does not include campaign contributions, dark money, state-level spending, or the invisible subsidy of the revolving door. The true cost of capture is incalculable. What follows is the portion we can measure.

Pharmaceutical Lobbying

The largest lobbying sector in America — and the most effective.

The pharmaceutical industry is the single most prolific lobbying force in American politics. In 2025, the sector spent $451.8 million on federal lobbying — more than any other industry, more than oil and gas and defense combined. PhRMA, the industry's primary trade association, spent $31.7 million in 2024 alone, maintaining a permanent operation of hundreds of registered lobbyists who outnumber the staffs of most congressional committees.

For more than two decades, this apparatus achieved something remarkable: it blocked Medicare — the largest single drug purchaser in the United States, covering 65 million Americans — from negotiating prescription drug prices. Every other major government buyer negotiates. The VA negotiates. Medicaid negotiates. The British NHS negotiates. Medicare was prohibited from doing so by law. That law was not an accident of policy. It was a product of sustained political investment: roughly $4 million per year in dark money to protect an estimated $8 billion annual windfall.

When the Inflation Reduction Act of 2022 finally introduced limited Medicare drug price negotiation, the pharmaceutical industry's response was immediate and overwhelming. It deployed 545 registered lobbyists to Capitol Hill — a ratio of roughly 20 lobbyists for every member of the relevant committees. It filed nine or more lawsuits challenging the program's constitutionality. The bill passed, but in dramatically weakened form: only ten drugs in the first year, with negotiations delayed and phased in over years.

The revolving door greased the machine. Billy Tauzin, who chaired the House Energy and Commerce Committee and shepherded the legislation that barred Medicare from negotiating, left Congress to become president of PhRMA at a salary exceeding $2 million per year. His case is not an outlier. It is a template. The lawmakers who protect the industry are rewarded by the industry, and the pipeline from Capitol Hill to K Street runs so smoothly that it barely makes news.

The result: Americans pay two to three times more for prescription drugs than citizens of any other developed nation. Insulin that costs $10 in Canada costs $300 here. Cancer treatments priced at $50,000 abroad sell for $150,000 domestically. The pharmaceutical industry argues that high prices fund innovation. But over half of transformative drug research is funded by the NIH — with taxpayer money. The public pays twice: once for the research, and again at the pharmacy counter.

Fossil Fuels

$100-150 million in annual lobbying to protect $20 billion in annual subsidies.

The fossil fuel industry's political operation is less a lobbying effort than a permanent counterinsurgency campaign. Oil and gas companies spend between $100 million and $150 million per year on federal lobbying. In return, the industry receives more than $20 billion annually in federal subsidies, tax breaks, and preferential regulatory treatment — subsidies that persist through Democratic and Republican administrations alike, through oil booms and climate emergencies, through record-breaking profits and catastrophic spills.

The industry's legislative victories are measured not in bills passed but in bills killed. Fossil fuel lobbying helped destroy cap-and-trade legislation that had bipartisan support. It weakened the Clean Power Plan. It diluted the climate provisions of the Build Back Better Act until the bill's environmental ambitions were a fraction of their original scope. The Koch network alone has channeled hundreds of millions of dollars into energy policy influence, funding think tanks, academic chairs, state-level advocacy groups, and direct campaign contributions designed to make climate legislation politically radioactive.

The industry's most effective weapon is the ballot measure campaign. In 2018, Colorado's Proposition 112 would have required fracking setbacks from homes and schools. The oil and gas industry spent $41 million to defeat it — in a state ballot measure. The same year, Washington state's Initiative 1631, which would have imposed a carbon fee, was defeated after the industry poured $29.7 million into opposition advertising. In both cases, the industry outspent supporters by margins so vast that the contests were effectively over before they began. This is not democracy in action. It is democracy for sale.

The Common Playbook

Despite operating in vastly different sectors, these four industries follow an identical pattern of political capture. First, they invest in lobbying at a scale that dwarfs any opposing force. Second, they hire former regulators and lawmakers who understand the system from the inside. Third, they distribute economic benefits — jobs, contracts, research grants — across enough congressional districts to make opposition politically painful. Fourth, when reform movements gather momentum, they deploy overwhelming resources to dilute, delay, or destroy legislation before it reaches a vote.

The playbook works because the costs are concentrated and the benefits are diffuse. A pharmaceutical company that spends $30 million on lobbying to protect a single drug's pricing power is making a rational investment with a clear return. The millions of Americans who pay inflated prices have no comparable mechanism for collective action. A defense contractor that maintains suppliers in 45 states is not inefficient — it is building a political firewall. A fossil fuel company that spends $41 million to defeat a ballot measure is not wasting money — it is protecting $20 billion in annual subsidies.

The asymmetry is the point. Industry capture persists not because voters approve of it, but because the forces defending the status quo will always outspend the forces challenging it. Reforming drug pricing, cutting defense waste, eliminating fossil fuel subsidies, and regulating Big Tech are all popular positions in public polling. They are also positions that threaten hundreds of billions of dollars in corporate revenue. The industries in this chapter have demonstrated, repeatedly and with mathematical precision, that political spending is the highest-return investment available in the American economy. Until the cost of capture exceeds the cost of compliance, the cycle will continue.